Cargando…
LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer
(1) Background: Liver kinase B1 (LKB1) is a tumor suppressor gene involved in cell growth and metabolism. However, its alterations are not routinely assessed for guiding therapy in clinical practice. We assessed LKB1 expression by immunohistochemistry as a potential biomarker. (2) Methods: This bice...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857995/ https://www.ncbi.nlm.nih.gov/pubmed/36661676 http://dx.doi.org/10.3390/curroncol30010027 |
_version_ | 1784873988049076224 |
---|---|
author | Avilés-Salas, Alejandro Díaz-García, Diego A. Lara-Mejía, Luis Cardona, Andrés F. Orozco-Morales, Mario Catalán, Rodrigo Hernández-Pedro, Norma Y. Rios-Garcia, Eduardo Ramos-Ramírez, Maritza Arrieta, Oscar |
author_facet | Avilés-Salas, Alejandro Díaz-García, Diego A. Lara-Mejía, Luis Cardona, Andrés F. Orozco-Morales, Mario Catalán, Rodrigo Hernández-Pedro, Norma Y. Rios-Garcia, Eduardo Ramos-Ramírez, Maritza Arrieta, Oscar |
author_sort | Avilés-Salas, Alejandro |
collection | PubMed |
description | (1) Background: Liver kinase B1 (LKB1) is a tumor suppressor gene involved in cell growth and metabolism. However, its alterations are not routinely assessed for guiding therapy in clinical practice. We assessed LKB1 expression by immunohistochemistry as a potential biomarker. (2) Methods: This bicentric retrospective cohort study analyzed data from patients with advanced NSCLC who initiated platinum-based chemotherapy or epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) between January 2016 and December 2020. Kaplan–Meier and Cox regression models were used for survival curves and multivariate analysis. (3) Results: 110 patients were evaluated, and the clinical stage IV predominated the lung adenocarcinoma histology. LKB1 loss was observed in 66.3% of cases. LKB1 loss was associated with non-smokers, the absence of wood smoke exposure and an EGFR wild-type status. The median progression-free survival (PFS) and overall survival (OS) in the population were 11.1 and 26.8 months, respectively, in the loss group, compared with cases exhibiting a positive expression. After an adjustment by age, smoking status, Eastern Cooperative Oncology Group Performance Score (ECOG-PS), EGFR status and type of administered therapy, LKB1 loss was significantly associated with worse PFS and OS. (4) Conclusion: Patients with an LKB1 loss had worse clinical outcomes. This study warrants prospective assessments to confirm the prognostic role of the LKB1 expression in advanced NSCLC. |
format | Online Article Text |
id | pubmed-9857995 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98579952023-01-21 LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer Avilés-Salas, Alejandro Díaz-García, Diego A. Lara-Mejía, Luis Cardona, Andrés F. Orozco-Morales, Mario Catalán, Rodrigo Hernández-Pedro, Norma Y. Rios-Garcia, Eduardo Ramos-Ramírez, Maritza Arrieta, Oscar Curr Oncol Article (1) Background: Liver kinase B1 (LKB1) is a tumor suppressor gene involved in cell growth and metabolism. However, its alterations are not routinely assessed for guiding therapy in clinical practice. We assessed LKB1 expression by immunohistochemistry as a potential biomarker. (2) Methods: This bicentric retrospective cohort study analyzed data from patients with advanced NSCLC who initiated platinum-based chemotherapy or epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) between January 2016 and December 2020. Kaplan–Meier and Cox regression models were used for survival curves and multivariate analysis. (3) Results: 110 patients were evaluated, and the clinical stage IV predominated the lung adenocarcinoma histology. LKB1 loss was observed in 66.3% of cases. LKB1 loss was associated with non-smokers, the absence of wood smoke exposure and an EGFR wild-type status. The median progression-free survival (PFS) and overall survival (OS) in the population were 11.1 and 26.8 months, respectively, in the loss group, compared with cases exhibiting a positive expression. After an adjustment by age, smoking status, Eastern Cooperative Oncology Group Performance Score (ECOG-PS), EGFR status and type of administered therapy, LKB1 loss was significantly associated with worse PFS and OS. (4) Conclusion: Patients with an LKB1 loss had worse clinical outcomes. This study warrants prospective assessments to confirm the prognostic role of the LKB1 expression in advanced NSCLC. MDPI 2022-12-26 /pmc/articles/PMC9857995/ /pubmed/36661676 http://dx.doi.org/10.3390/curroncol30010027 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Avilés-Salas, Alejandro Díaz-García, Diego A. Lara-Mejía, Luis Cardona, Andrés F. Orozco-Morales, Mario Catalán, Rodrigo Hernández-Pedro, Norma Y. Rios-Garcia, Eduardo Ramos-Ramírez, Maritza Arrieta, Oscar LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer |
title | LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer |
title_full | LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer |
title_fullStr | LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer |
title_full_unstemmed | LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer |
title_short | LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer |
title_sort | lkb1 loss assessed by immunohistochemistry as a prognostic marker to first-line therapy in advanced non-small-cell lung cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857995/ https://www.ncbi.nlm.nih.gov/pubmed/36661676 http://dx.doi.org/10.3390/curroncol30010027 |
work_keys_str_mv | AT avilessalasalejandro lkb1lossassessedbyimmunohistochemistryasaprognosticmarkertofirstlinetherapyinadvancednonsmallcelllungcancer AT diazgarciadiegoa lkb1lossassessedbyimmunohistochemistryasaprognosticmarkertofirstlinetherapyinadvancednonsmallcelllungcancer AT laramejialuis lkb1lossassessedbyimmunohistochemistryasaprognosticmarkertofirstlinetherapyinadvancednonsmallcelllungcancer AT cardonaandresf lkb1lossassessedbyimmunohistochemistryasaprognosticmarkertofirstlinetherapyinadvancednonsmallcelllungcancer AT orozcomoralesmario lkb1lossassessedbyimmunohistochemistryasaprognosticmarkertofirstlinetherapyinadvancednonsmallcelllungcancer AT catalanrodrigo lkb1lossassessedbyimmunohistochemistryasaprognosticmarkertofirstlinetherapyinadvancednonsmallcelllungcancer AT hernandezpedronormay lkb1lossassessedbyimmunohistochemistryasaprognosticmarkertofirstlinetherapyinadvancednonsmallcelllungcancer AT riosgarciaeduardo lkb1lossassessedbyimmunohistochemistryasaprognosticmarkertofirstlinetherapyinadvancednonsmallcelllungcancer AT ramosramirezmaritza lkb1lossassessedbyimmunohistochemistryasaprognosticmarkertofirstlinetherapyinadvancednonsmallcelllungcancer AT arrietaoscar lkb1lossassessedbyimmunohistochemistryasaprognosticmarkertofirstlinetherapyinadvancednonsmallcelllungcancer |